A federal consultative group voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was tight. It is not binding. The FDA has given no clear statement on whether it will follow the advice. The move came after weeks of community hearings. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could change how the agency handles a part of the wellness market that is expanding rapidly. Industry players are waiting to see if the agency adopts the plan. A spokesperson offered no deadline for a follow-up. Critics argue the change would grant more access to substances some say help. Safety voices warn that looser rules could open the door to misuse across a barely regulated market. The panel vote only plants the seed for a shift, and the last word rests with the agency.
Sources & References
-
FDA panel recommends loosening restrictions on controversial peptide - The Washington Post
FDA panel recommends loosening restrictions on controversial peptide The Washington Post
-
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition - Time Magazine
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition Time Magazine
-
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week - The American Journal of Managed Care
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week The American Journal of Managed Care
-
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers - AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers AP News
-
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. - MarketWatch
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. MarketWatch